N19 the Impact of Extra-Retroperitoneal Masses in Patients With Advanced Nonseminomatous Testicular Tumors

Argirovic, D.; Argirović, A.; Stanic, Vojkan

doi:10.1016/s1569-9056(10)61223-7

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients were treated with chemotherapy for metastatic NSTT at initial presentation and subsequently underwent PC-RPLA. Patient undergoing extra-retroperitoneal surgery were not included in this study because our previous analysisdemonstrated that these patients may be at risk of progression independently of tumor histology 4 .…”

Section: Methodsmentioning

confidence: 99%

“…Although testicular cancer is highly curable it requires appropriate management at all stages 2 . Inappropriate management increases the morbidity, mortality and the burden of therapy for the patient 3,4 .…”

Section: Introductionmentioning

confidence: 99%

“…Inhibition of production and release of gonadotropins (releasing hormone analogues) can lead to severe forms of oligospermia or azoospermia, and to the castration syndrome. Application of testosterone at a dose of 200mg a week for 12 weeks can lead to reversible restraint in the secretion of FSH and LH and associated oligospermia, but as it is not a phenomenon of all men, this method is not an effective contraceptive method 4 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Can we predict the presence of teratoma in the retroperitoneum before post-chemotherapy retroperitoneal lymphadenectomy?

Argirović¹,

Argirović²

2015

Mat Med

View full text Add to dashboard Cite

The biological potential of teratoma remains unpredictable, therefore identifying its presence in the retroperitoneum remains important. We evaluated patients undergoing post-chemothe rapy retroperitoneal lymphadenectomy (PC-RPLA) for nonseminomatous testicular tumors (NSTT), to determine predictors of teratomatous elements in the retroperitoneum. We identified 161 patients from 1982 to 2005 who underwent PC-RPLA for metastatic NSTT. Multiple clinical and pathological variables were reviewed from out RPLA database. Of the 161 patients in our series, 112 (70%) received only induction chemotherapy and 49 (30%) required 2nd line chemotherapy. Studies of retroperitoneal pathology demonstrated the presence of fibrosis in 44 (27%), teratoma in 82 (51%) and vital carcinoma in 35(22%).Among 82 patients (51%) with finding of teratomatous elements at PC-RPLA, we revealed the presence ofmature teratoma in 85%, immature teratoma in 12% and teratoma with malignant transformation in 3%. Of the 99 patients (61%) with teratomatous elements in the primary NSTT, 61 (62%) had teratoma at PC-RPLA. Even in the absence of teratoma in the primary NSTT, teratoma was present in the retroperitoneum in 21 of 62 patients (32%)(p<0.0001). All patients had normal values of serum tumor markers (STM) at PC-RPLA. Post-chemotherapy retroperitoneal residual mass measuring <2 cm, from 2.1-5.0 cm and > 5 cm in diameter occured in 30%, 52% and 55%, respectively. By multivariate analysis , teratoma in the orchiectomy specimen (p<0.005), relative change in nodal size before and after chemotherapy (p<0.005), and no requirement for 2nd line chemotherapy (p=0.33) were independent predictors for the presence of the teratoma in the retroperitoneum. Teratoma remains

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation